EU to terminate vaccine agreement with Valneva

A lacking marketing approval has allowed the European Commission to terminate its Covid-19 vaccine purchasing agreement with Valneva.
Photo: David Vincent/AP/Ritzau Scanpix
Photo: David Vincent/AP/Ritzau Scanpix
by marketwire, translated by daniel pedersen

On Monday, French vaccine maker Valneva is being punished by investors on the Paris stock exchange following news that the EU is intending to terminate its purchasing agreement on Covid-19 vaccines.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading